Skip to main content

Table 3 Analysis of factors correlated with urinary glucose changes at day 7 of SGLT2 inhibitor treatment

From: Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring

 

ΔUrinary glucose

p value

ΔMBG

0.239

0.272

ΔSD

−0.468*

0.024

ΔCV

−0.654**

0.001

ΔTime at >140 mg/dL

0.352

0.100

ΔTime at <70 mg/dL

−0.277

0.201

ΔTime at 70–140 mg/dL

−0.314

0.144

ΔMAGE

−0.520*

0.011

ΔLAGE

−0.465*

0.025

ΔM value

0.103

0.640

ΔMPPGE

−0.436*

0.038

ΔMax

−0.027

0.904

ΔMin

0.418*

0.047

  1. Data are results of Pearson correlation analysis of variables with normal distribution (ΔSD, ΔCV, ΔTime at >140 mg/dL, ΔTime at 70–140 mg/dL, ΔMAGE, ΔLAGE, ΔMMPGE and ΔMax) and Spearman rank correlation for variables with skewed distribution
  2. IRI Immunoreactive insulin, HbA1c glycated hemoglobin, CPR C peptide immunoreactivity, eGFR estimated glomerular filtration rate, CGM continuous glucose monitoring, SGLT2-I sodium glucose cotransporter 2 inhibitor, MBG mean blood glucose, SD standard deviation, CV coefficient of variation, MAGE mean amplitude of glycemic excursions, LAGE largest amplitude of glycemic excursions, MPPGE mean postprandial glucose excursions, BG blood glucose, BB before breakfast, AB after breakfast, BL before lunch, AL after lunch, BD before dinner, AD after dinner
  3. * p < 0.05, ** p < 0.01
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us